Perrigo named German packaging firm executive Uwe Rohrhoff as CEO, replacing John Hendrickson, effective Jan. 15. The former head of Gerresheimer will bring experience leading a global business that included 36 manufacturing facilities across 14 countries and sales of $1.7bn.
The experience Perrigo Co. PLC’s next chief executive, Uwe Rohrhoff, has leading a global firm that provides pharmaceutical packaging points to improving the OTC private label giant's operations and organization, analysts anticipate.
An early item on Rohrhoff's to-do list when he joins Perrigo on Jan. 15 likely will be considering whether the firm will keep its Rx generics business. The 11-member board...
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.
The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.
Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.
